Clinical Trials · NCT01720446

Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes

Name: Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

CompletedPhase 3Semaglutide

Phase: Phase 3
Recruitment status: Completed
Sponsor: Novo Nordisk A/S
Enrollment: 3,297
Start date: Feb 2013
Locations: 253 sites, 21 countries
Primary endpoint: Time From Randomisation to First Occurrence of a MACE, Defined as Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke

View Semaglutide compound reference